DGX Quest Diagnostics
NYSE · SEC CIK 1022079 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $37.31M 23 sales by 8 insiders
- Filings on record
- 341 since 2021-07-06, latest 2026-09-03 17:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Davis J. E. | CEO, Pres, Dir | — | $17.08M |
| Doherty Catherine T. | EVP, Regional Businesses | — | $6.96M |
| PREVOZNIK MICHAEL E | SVP, GC | — | $6.69M |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | — | $2.17M |
| Plewman Patrick | SVP for Diagnostic Services | — | $2.03M |
| DELANEY MARK E | SVP, Chief Commercial Off | — | $1.86M |
| PFEIFFER GARY M | Dir | — | $270.3K |
| Gregg Vicky B | Dir | — | $239.7K |
| Lassiter Wright III | Dir | — | — |
| Deppe Michael J | SVP, CAO, Corp. Ctrl | — | — |
Transactions 434
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-24 | 2025-10-21 | DGX | CARTER ROBERT B | Dir | A - Grant | $189.09 | +6 | 2,698 | +0.2% | +$1,135 | |
| D | 2025-10-24 | 2025-10-22 | DGX | PFEIFFER GARY M | Dir | S - Sale | $182.40 | -1,482 | 29.4K | -5% | -$270.3K |
| 2025-10-24 | 2025-10-21 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $189.08 | +15 | 7,530 | +0.2% | +$2,836 | |
| 2025-10-24 | 2025-10-21 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $189.08 | +68 | 25.7K | +0.3% | +$12.9K | |
| 2025-10-24 | 2025-10-21 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $189.08 | +46 | 15.3K | +0.3% | +$8,698 | |
| 2025-10-24 | 2025-10-21 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $189.08 | +15 | 8,379 | +0.2% | +$2,836 | |
| 2025-10-24 | 2025-10-21 | DGX | Gregg Vicky B | Dir | A - Grant | $189.08 | +70 | 18.3K | +0.4% | +$13.2K | |
| D | 2025-09-30 | 2025-09-26 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $103.57 | +227 | 38.3K | +0.6% | +$23.5K |
| DM | 2025-09-30 | 2025-09-26 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale+OE | $188.13 | -227 | 38.1K | -0.6% | -$42.7K |
| DM | 2025-09-25 | 2025-09-23+ | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale+OE | $187.12 | -28.5K | 38.1K | -43% | -$5.33M |
| DM | 2025-09-25 | 2025-09-23+ | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $103.57 | +28.5K | 38.3K | +290% | +$2.95M |
| 2025-08-25 | 2025-08-21 | DGX | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $185.00 | -1,975 | 15.3K | -11% | -$365.4K | |
| D | 2025-08-21 | 2025-08-19 | DGX | Plewman Patrick | SVP for Diagnostic Services | M - OptEx | $112.17 | +4,532 | 21.8K | +26% | +$508.4K |
| D | 2025-08-21 | 2025-08-19 | DGX | Plewman Patrick | SVP for Diagnostic Services | S - Sale+OE | $183.00 | -4,532 | 17.2K | -21% | -$829.4K |
| 2025-08-19 | 2025-08-15 | DGX | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $180.00 | -1,975 | 17.2K | -10% | -$355.5K | |
| 2025-08-15 | 2025-08-13 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $175.91 | -123 | 8,338 | -1% | -$21.6K | |
| DM | 2025-08-08 | 2025-08-06 | DGX | Plewman Patrick | SVP for Diagnostic Services | S - Sale+OE | $175.00 | -5,535 | 21.2K | -21% | -$968.6K |
| D | 2025-08-08 | 2025-08-06 | DGX | Plewman Patrick | SVP for Diagnostic Services | M - OptEx | $86.63 | +3,560 | 24.7K | +17% | +$308.4K |
| DM | 2025-08-01 | 2025-07-30 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M - OptEx | $102.77 | +8,269 | 15.9K | +109% | +$849.8K |
| DM | 2025-08-01 | 2025-07-30+ | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale+OE | $167.95 | -10.5K | 10.7K | -50% | -$1.76M |
| 2025-07-25 | 2025-07-21 | DGX | Gregg Vicky B | Dir | L - Small Acq | $167.50 | +79 | 18.2K | +0.4% | +$13.2K | |
| 2025-07-25 | 2025-07-21 | DGX | Lassiter Wright III | Dir | L - Small Acq | $167.51 | +7 | 9,044 | +0.1% | +$1,173 | |
| 2025-07-25 | 2025-07-21 | DGX | SAMAD SAM | EVP, CFO | L - Small Acq | $167.50 | +72 | 25.7K | +0.3% | +$12.1K | |
| 2025-07-25 | 2025-07-21 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $167.49 | +17 | 7,515 | +0.2% | +$2,847 | |
| 2025-07-25 | 2025-07-21 | DGX | CARTER ROBERT B | Dir | L - Small Acq | $167.51 | +7 | 2,692 | +0.3% | +$1,173 | |
| 2025-07-25 | 2025-07-21 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L - Small Acq | $167.50 | +27 | 10.7K | +0.3% | +$4,522 | |
| 2025-07-25 | 2025-07-21 | DGX | Plewman Patrick | SVP for Diagnostic Services | L - Small Acq | $167.49 | +80 | 21.2K | +0.4% | +$13.4K | |
| 2025-07-17 | 2025-07-16 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $169.01 | -850 | 25.6K | -3% | -$143.7K | |
| 2025-05-19 | 2025-05-15 | DGX | MORRISON DENISE M | Dir | A - Grant | $0.00 | +1,203 | 10.7K | +13% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | RING TIMOTHY M | Dir | A - Grant | $0.00 | +1,203 | 29.5K | +4% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | Doi Tracey | Dir | A - Grant | $0.00 | +1,203 | 6,490 | +23% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | Gregg Vicky B | Dir | A - Grant | $0.00 | +1,203 | 18.1K | +7% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | CARTER ROBERT B | Dir | A - Grant | $0.00 | +1,203 | 2,685 | +81% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | PFEIFFER GARY M | Dir | A - Grant | $0.00 | +1,203 | 30.7K | +4% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | Diaz Luis | Dir | A - Grant | $0.00 | +1,203 | 4,054 | +42% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | Lassiter Wright III | Dir | A - Grant | $0.00 | +1,203 | 9,037 | +15% | $0 | |
| 2025-05-19 | 2025-05-15 | DGX | MAIN TIMOTHY L | Dir | A - Grant | $0.00 | +1,203 | 26.3K | +5% | $0 | |
| M | 2025-05-14 | 2025-05-12+ | DGX | DELANEY MARK E | SVP, Chief Commercial Off | S - Sale | $175.51 | -1,748 | 7,498 | -19% | -$306.8K |
| 2025-05-02 | 2025-04-21 | DGX | Plewman Patrick | SVP for Diagnostic Services | L - Small Acq | $164.42 | +81 | 21.1K | +0.4% | +$13.3K | |
| 2025-05-02 | 2025-04-21 | DGX | Gregg Vicky B | Dir | A - Grant | $164.42 | +68 | 16.9K | +0.4% | +$11.2K | |
| 2025-05-02 | 2025-04-21 | DGX | SAMAD SAM | EVP, CFO | L - Small Acq | $164.42 | +74 | 26.5K | +0.3% | +$12.2K | |
| 2025-05-02 | 2025-04-21 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L - Small Acq | $164.42 | +27 | 10.6K | +0.3% | +$4,439 | |
| 2025-05-02 | 2025-04-21 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $164.42 | +25 | 9,246 | +0.3% | +$4,110 | |
| 2025-04-04 | 2025-04-02 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale | $170.00 | -2,555 | 10.6K | -19% | -$434.4K | |
| M | 2025-04-04 | 2025-04-02 | DGX | Davis J. E. | CEO, Pres, Dir | S - Sale | $168.46 | -39.2K | 131.3K | -23% | -$6.60M |
| 2025-03-28 | 2025-03-26 | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $166.71 | -162 | 21.0K | -0.8% | -$27.0K | |
| 2025-03-28 | 2025-03-26 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $166.71 | -256 | 9,221 | -3% | -$42.7K | |
| 2025-03-19 | 2025-03-17 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $170.00 | -4,643 | 38.1K | -11% | -$789.3K | |
| 2025-03-07 | 2025-03-05 | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $174.13 | -5,370 | 68.1K | -7% | -$935.1K | |
| 2025-03-05 | 2025-03-04 | DGX | Doherty Catherine T. | EVP, Regional Businesses | A - Grant | $173.74 | +10.4K | 78.4K | +15% | +$1.80M | |
| 2025-03-05 | 2025-03-04 | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $175.79 | -716 | 68.1K | -1% | -$125.9K | |
| M | 2025-03-05 | 2025-03-03+ | DGX | Doherty Catherine T. | EVP, Regional Businesses | F - Tax | $173.74 | -5,404 | 68.8K | -7% | -$938.9K |
| M | 2025-03-05 | 2025-03-03+ | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $173.74 | -2,871 | 10.6K | -21% | -$498.8K |
| 2025-03-05 | 2025-03-04 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $173.74 | +4,434 | 15.0K | +42% | +$770.4K | |
| 2025-03-05 | 2025-03-04 | DGX | PREVOZNIK MICHAEL E | SVP, GC | A - Grant | $173.74 | +8,549 | 46.7K | +22% | +$1.49M | |
| 2025-03-05 | 2025-03-04 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $175.79 | -592 | 38.1K | -2% | -$104.1K | |
| M | 2025-03-05 | 2025-03-03+ | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $173.74 | -4,228 | 42.8K | -9% | -$734.6K |
| M | 2025-03-05 | 2025-03-03+ | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $173.74 | -2,386 | 17.8K | -12% | -$414.5K |
| 2025-03-05 | 2025-03-04 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $173.74 | +5,674 | 23.4K | +32% | +$985.8K | |
| 2025-03-05 | 2025-03-04 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $173.74 | +61.9K | 198.5K | +45% | +$10.76M | |
| M | 2025-03-05 | 2025-03-03+ | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $173.74 | -33.3K | 166.8K | -17% | -$5.79M |
| 2025-03-05 | 2025-03-04 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | A - Grant | $173.74 | +1,711 | 35.2K | +5% | +$297.3K | |
| M | 2025-03-05 | 2025-03-03+ | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | F - Tax | $173.74 | -2,559 | 34.4K | -7% | -$444.6K |
| 2025-03-05 | 2025-03-04 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $173.74 | -7,684 | 26.4K | -23% | -$1.34M | |
| 2025-03-05 | 2025-03-04 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $173.74 | +13.9K | 34.1K | +69% | +$2.41M | |
| 2025-03-05 | 2025-03-04 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $173.74 | +5,317 | 11.3K | +89% | +$923.8K | |
| 2025-03-05 | 2025-03-04 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $173.74 | -1,823 | 9,477 | -16% | -$316.7K | |
| 2025-02-28 | 2025-02-26 | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $171.75 | -229 | 17.9K | -1% | -$39.3K | |
| 2025-02-28 | 2025-02-26 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $171.75 | -214 | 5,983 | -3% | -$36.8K | |
| 2025-02-28 | 2025-02-26 | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $171.75 | -2,966 | 138.2K | -2% | -$509.4K | |
| 2025-02-28 | 2025-02-26 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | F - Tax | $171.75 | -88 | 35.2K | -0.2% | -$15.1K | |
| 2025-02-28 | 2025-02-26 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $171.75 | -869 | 20.2K | -4% | -$149.3K | |
| 2025-02-28 | 2025-02-27 | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $172.61 | -824 | 69.2K | -1% | -$142.2K | |
| 2025-02-28 | 2025-02-26 | DGX | Doherty Catherine T. | EVP, Regional Businesses | F - Tax | $171.75 | -455 | 70.0K | -0.6% | -$78.1K | |
| 2025-02-28 | 2025-02-26 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $171.75 | -233 | 11.5K | -2% | -$40.0K | |
| 2025-02-28 | 2025-02-26 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $171.75 | -286 | 39.6K | -0.7% | -$49.1K | |
| 2025-02-28 | 2025-02-27 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $172.61 | -528 | 39.0K | -1% | -$91.1K | |
| 2025-02-21 | 2025-02-19 | DGX | Plewman Patrick | SVP for Diagnostic Services | S - Sale | $169.71 | -320 | 18.1K | -2% | -$54.3K | |
| 2025-02-21 | 2025-02-19 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $169.71 | -242 | 6,197 | -4% | -$41.1K | |
| 2025-02-21 | 2025-02-19 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $169.71 | -1,031 | 21.0K | -5% | -$175.0K | |
| M | 2025-02-21 | 2025-02-19+ | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $170.51 | -1,434 | 71.4K | -2% | -$244.5K |
| 2025-02-21 | 2025-02-19 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $169.71 | -287 | 11.8K | -2% | -$48.7K | |
| 2025-02-21 | 2025-02-19 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $169.71 | -374 | 40.4K | -0.9% | -$63.5K | |
| 2025-02-21 | 2025-02-20 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $170.99 | -604 | 39.8K | -1% | -$103.3K | |
| 2025-02-21 | 2025-02-19 | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $169.71 | -2,936 | 141.2K | -2% | -$498.3K | |
| 2025-02-21 | 2025-02-19 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | F - Tax | $169.71 | -99 | 35.3K | -0.3% | -$16.8K | |
| D | 2025-02-14 | 2025-02-12 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $0.00 | +2,042 | 18.4K | +12% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $0.00 | +4,538 | 22.1K | +26% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | A - Grant | $0.00 | +454 | 35.4K | +1% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $0.00 | +18.1K | 144.1K | +14% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | PREVOZNIK MICHAEL E | SVP, GC | A - Grant | $0.00 | +2,345 | 40.8K | +6% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $0.00 | +1,815 | 6,439 | +39% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | Doherty Catherine T. | EVP, Regional Businesses | A - Grant | $0.00 | +3,479 | 71.9K | +5% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $0.00 | +2,269 | 12.1K | +23% | $0 |
| 2025-02-07 | 2025-02-05 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | S - Sale | $164.30 | -403 | 4,624 | -8% | -$66.2K | |
| 2025-02-07 | 2025-02-05 | DGX | Gregg Vicky B | Dir | S - Sale | $164.57 | -1,250 | 16.9K | -7% | -$205.7K | |
| 2025-01-31 | 2025-01-29 | DGX | Gregg Vicky B | Dir | L - Small Acq | $158.04 | +72 | 18.1K | +0.4% | +$11.4K | |
| 2025-01-31 | 2025-01-29 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L - Small Acq | $158.03 | +12 | 9,780 | +0.1% | +$1,896 | |
| 2025-01-31 | 2025-01-29 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $158.03 | +4 | 5,027 | +0.1% | +$632.12 | |
| 2025-01-31 | 2025-01-29 | DGX | Plewman Patrick | SVP for Diagnostic Services | L - Small Acq | $158.04 | +57 | 16.3K | +0.3% | +$9,008 |
Purchase Sale Sale after option exercise All abbreviations